👁️ 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗶𝗻 𝗟𝗼𝗻𝗱𝗼𝗻 𝘁𝗼 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗲𝘆𝗲–𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝗮𝘅𝗶𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗢𝗽𝗵𝘁𝗵𝗮𝗹𝗺𝗼𝗹𝗼𝗴𝘆 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗨𝗞 (𝗠𝗢𝗦𝗨𝗞) 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟳 📅 Wednesday 24 February 2027 | 09.00–17.00 📍 International Students House, Lo...

Team: Ultrasound Avengers / Halo Heroes Base article: Sebastian A, van der Geest KSM, Tomelleri A, Macchioni P, Klinowski G, Salvarani C, Prieto-Peña D, Conticini E, Khurshid M, Dagna L, Brouwer E, Da...

Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.

An investigation shows the orbital MRI features that can help to earlier diagnose patients with giant cell arteritis.

The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

Investing.com -- Novartis (SIX:NOVN) announced Thursday that its Cosentyx drug did not meet its primary goal in a Phase III trial for adults with giant cell arteritis (GCA). The drug failed to demonstrate an improvement in sustained remission among patients with newly diagnosed or relapsing GCA, according to the Swiss pharmaceutical company. Shreeram Aradhye, president of development and chief medical officer at Novartis, said: "While the Phase III results did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases." This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Disease-associated vision changes are common in GCA, with no significant difference in visual improvement observed with IV glucocorticoids vs oral therapy.